Bristol-Myers Squibb BMY

HealthcareMarket cap $140B3 connections

Bristol-Myers Squibb makes Opdivo and Yervoy (cancer immunotherapy), Eliquis (blood thinner, $12B+ annually), Revlimid (multiple myeloma), and Camzyos (hypertrophic cardiomyopathy). Its $74B Celgene acquisition was the largest pharma deal of its era. BMS's oncology and cardiovascular portfolios make it one of the most important pharmaceutical companies in medicine.

Explore Bristol-Myers Squibb on the interactive map Relationship timeline Find a path to another company

Partners 1

Strategic partnerships, joint products and alliances

Prime MedicineHealthcare · $1BPrime Medicine and BMS cell-therapy collaboration (2024)since 2024

Stakes owned 2

Companies Bristol-Myers Squibb owns or has invested in

Karuna TherapeuticsHealthcare · $13BBristol-Myers Squibb acquired Karuna for $14Bsince 2024
Turning Point TherapeuticsHealthcare · $4BBristol Myers Squibb acquired Turning Point Therapeutics (2022)since 2022

Other Healthcare companies

Eli Lilly UnitedHealth Novo Nordisk Johnson & Johnson AbbVie Merck AstraZeneca Thermo Fisher Novartis Abbott Labs

Embed this on your site

Show Bristol-Myers Squibb's network in an article or report - it updates as our data does.

<iframe src="https://vexmap.com/embed.html?co=BMY" width="600" height="420" style="border:0;border-radius:12px;max-width:100%" title="Bristol-Myers Squibb on VexMap" loading="lazy"></iframe>

Preview

Relationships are compiled by VexMap from company filings, announcements and reporting, and last reviewed September 2026. Spotted something wrong? Tell us. Not investment advice.